Health
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif., May 08, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatmen
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/2e9f3cb5aec88b293d5073600fbf6715"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JGWqrpN5pU6PBN2ZpylGTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MA--/https://media.zenfs.com/en/business-wire.com/2e9f3cb5aec88b293d5073600fbf6715","width":960,"height":260},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.XZFBJjY8q1tgWVVAZqdoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3Mw--/https://media.zenfs.com/en/business-wire.com/2e9f3cb5aec88b293d5073600fbf6715","width":640,"height":173},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3z3NNjg4jkxyjulXrHqm7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA-/https://media.zenfs.com/en/business-wire.com/2e9f3cb5aec88b293d5073600fbf6715","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2026--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. The open label extension (OLE) portion of the PALISADE-4 study remains ongoing.","length":626,"tagName":"p"},{"type":"text","content":""The completion of the randomized portion of PALISADE-4 is another important step for our fasedienol Phase 3 program in social anxiety disorder, and we expect to announce topline results this quarter," said Shawn Singh, President and Chief Executive Officer. "We extend our sincere thanks to the participants, clinical investigators, site staff, and contract research organization whose hard work, collaboration, and commitment brought this portion of the study to completion."","length":497,"tagName":"p"},{"type":"text","content":"PALISADE-4 is a U.S...